AMRI moves forward with plan to close Wales API plant, cut 62 jobs

U.S. contract manufacturer AMRI ($AMRI) says that it will follow through with plans to close its API manufacturing site in Holywell, U.K., a move that will mean the loss of 62 jobs. The company in February said it was looking at closing the plant but would first have talks with employee representatives for the Wales facility. Last week, the drugmaker said that following the talks, the decision was made to move forward with the plant closing and that it would transfer the work to other facilities and close the Holywell plant by the end of the year. The decision follows AMRI's $60 million purchase in January of two Aptuit facilities, one in Glasgow, Scotland, that specializes in clinical stage manufacturing, and one in West Lafayette, IN, that provides analytical testing services. Release | More

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.